Doctors have labelled medicinal cannabis prescriptions a “bureaucratic nightmare” requiring “a massive learning curve”, as patients say people in pain cannot wait months for relief.
The Coronavirus pandemic is causing stress levels to rise. Luckily, Applied Cannabis Research has launched a new study investigating the use of medicinal cannabis as a treatment for anxiety.
The cost an average patient is spending on medicinal cannabis is going down and this week’s announced regulatory changes in Western Australia could see prices dropping even further.
Southern Cannabis Holdings (SCH) is pleased to announce that it has officially commenced operations in Australia and the United Kingdom. SCH is a multinational company that builds, integrates and operates businesses in pharmaceutical cannabis markets.
Cannabis has recently become one of the hottest investment sectors on world markets and despite Australia’s legal restrictions, the ASX has seen a flurry of pot stocks float in the last couple of years.
For, while customer numbers are going up 1000 per cent year-on-year, Southern Cannabis Holdings doesn’t advertise the exact addresses of its five medicinal cannabis clinics in Australia and one in New Zealand…
FreshLeaf Analytics, a Southern Cannabis Holdings (SCH) division, has released Australia’s most comprehensive medicinal cannabis Patient, Product and Pricing Analysis.
The Southern Cannabis Holding Company’s global research house, FreshLeaf Analytics, has just released its third report monitoring the products, patients and pricing of the Australian market.
This morning the company revealed that it has received Human Research Ethics Committee (HREC) approval to conduct a head-to-head clinical study on severe intractable epilepsy in collaboration with Cannabis Access Clinics and Epilepsy Action Australia.